The most important bets are rarely the obvious ones. Exoflare wasn't a trend. It was a signal.
Seeing the Gap Before It Becomes a Crisis
In venture capital, the easiest investments to explain are the ones everyone already understands. But the most important ones — the ones that genuinely matter — tend to arrive before the narrative catches up. When we first looked at Exoflare, biosecurity wasn’t a headline. It wasn’t a category that investors were rushing to define or founders were clamouring to enter. It was a quiet, largely unaddressed vulnerability sitting at the intersection of national security, public health, and critical infrastructure. That’s exactly why it caught our attention.
The Threat That Doesn’t Need a Passport
Biological threats don’t respect borders. They don’t require sophisticated delivery systems, vast resources, or state-level coordination. A single point of failure — an unmonitored supply chain, a gap in surveillance capability, an absence of early detection — can cascade into consequences that are deeply difficult to reverse. Australia, for all its geographic advantages, is not immune. And as global supply chains have grown more interconnected, the attack surface for biosecurity threats has expanded quietly alongside them. What struck us about Exoflare wasn’t just the technology. It was the clarity of problem they were solving and the precision of their approach to it. A purpose-built biosecurity threat management platform — not a pivot, not a feature, not a tool grafted from another use case. Something built from first principles for a problem that genuinely needed solving.
The Lesson We Keep Coming Back To
The best investments rarely feel obvious at the time. They feel necessary. Looking back, the question was never whether biosecurity would matter. It always mattered. The question was whether anyone would build the right infrastructure to address it — and whether we'd be willing to back that effort before the rest of the world caught on. We were. We're glad we were.
